Navigation Links
GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
Date:12/5/2008

is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. Additional clinical trials are in progress in rectal cancer, head and neck cancer, and melanoma. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and influenza. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filin
'/>"/>

SOURCE GenVec, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
2. ISTA Pharmaceuticals Announces Phase III Results for Once-Daily Topical Xibrom(TM) 0.09%
3. Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
4. Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
5. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
6. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
7. Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH
8. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
9. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
10. GeneThera Announces it is Set to Begin Commercial Testing for Johnes Disease as Soon as January, 2009.
11. Medarex Announces Initiation of Phase 1b Clinical Development Program with MDX-1106 for the Treatment of Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015  Seeger Weiss LLP is reporting ... issued a warning letter to C.R. Bard, the manufacturer of ... adequate strides to correct violations the agency found at two ... violations after the FDA cited them during Inspectional Observations that ... Bard,s Tempe, AZ , location and on ...
(Date:7/31/2015)...  Boston Children,s Hospital physicians report the first ... their anatomy before undergoing high-risk brain procedures. The ... the brain,s blood vessels) that posed special treatment ... Journal of Neurosurgery: Pediatrics , the physicians ... resins to create custom, high-fidelity models of the ...
(Date:7/31/2015)... -- Semler Scientific, Inc. (Nasdaq: SMLR ), a company ... and physician groups, today reported financial results for the ... "In the second quarter of 2015, Semler reported continued ... quarter over quarter revenue growth of 8%, and quarter ... units of 18%," said Doug Murphy-Chutorian, M.D., chief executive ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 33D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
... 24 PharmAthene, Inc.,(Amex: PIP ), a ... threats, announced today that the Company,is presenting two ... programs, Protexia(R) (rBChE) and Valortim(R) at the HHS,Public ... / BARDA Industry Day being held in Alexandria,VA, ...
... to Raise Awareness about,the Importance of Clinical Trial Participation, PHILADELPHIA, Sept. 24 ... be receptive to participating in clinical trials if ... survey of 6,000 cancer patients, 85 percent were either unaware ... trial was an option. ...
Cached Medicine Technology:PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop 7Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs 2Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs 3
(Date:7/31/2015)... ... July 31, 2015 , ... There’s no better way to ... it comes time to cook the next meal, making July the most appropriate to ... best grilling tips and recipes. , Make the next cookout different than the ones ...
(Date:7/31/2015)... Rolling Meadows, IL (PRWEB) , ... July 31, ... ... great ways to communicate. Rally Insurance Group, Inc. has re-branded their social media ... provides a personal way for consumers to communicate, find information, share insights ...
(Date:7/31/2015)... Washington, PA (PRWEB) , ... July 31, 2015 , ... ... specialties, is excited to launch three new Board Exam Courses. , The additions ... Smartest Doc Board Exam Prep from MDLinx makes preparing for the exam easy and ...
(Date:7/31/2015)... Los Angeles, CA (PRWEB) , ... July 31, 2015 , ... According to the ... the third floor of the Pasadena courthouse was contained and extinguished by the city’s fire ... one was in the building at the time of the fire, and it was a ...
(Date:7/31/2015)... ... 2015 , ... Well-known for its unique pastries and delicious confections, Pastry Palace, ... designs, making life just a little bit sweeter for newlyweds. A family-owned business, the ... orders one. , The bakery provides a full line of custom wedding cakes. Brides ...
Breaking Medicine News(10 mins):Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 2Health News:MDLinx Offers Three New Board Exam Prep Courses - Gastroenterology, Pulmonology and Allergy/Immunology 3Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 2Health News:Article on Recent Pasadena Courtroom Fire Highlights the Effectiveness of Fire Alarm Systems, Says Fire Protection Group Inc 3Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... small reduction in LDL cholesterol can contribute to far reaching ... to a US study, scientists have said that even a ... is amply found in the dairy products, meat and hydrogenated ... nearly 50%. ,The study on this subject was ...
... claim that more people could be at risk of ... previously thought after new evidence emerged that the condition ... to the scientists from Edinburgh a long incubation period ... blood transfusions and surgical instruments, can become a significant ...
... physicians who provide free care to the poor has ... becoming huge problem for America’s quickly growing number of ... conducted by the Center for Studying Health System Change, ... care in the mid-1990s, compared with about two-thirds now. ...
... patients who participated in a UC Davis study of ... blood pressure. // ,Conducted by UC Davis ... trial to assess the effect of grape seed extract ... factors that increase the risk for heart disease, including ...
... are well aware of Kawasaki as a motorcycle rather than ... doctors informed that his 9 year old daughter, Utkarsha was ... so as it is prevalent among Korean and Japanese children. ... that Kawasaki was a disease,' remarked Dinesh Ghai. ...
... world tuberculosis day. It was thought decades ago that the ... still remains a major // threat and its toll still ... rising at almost 1% every year despite the efforts taken ... globally in 2004 and infected nearly 9 million, according to ...
Cached Medicine News:Health News:Mad Cow Disease – Worst Is Yet To com 2Health News:Fewer Doctors Treating For Free 2Health News:High Blood Pressure Can Be Treated With Grape Seed Extract 2Health News:Low Awareness Of Kawasaki Disease In Capital: Parents Form Support Group 2Health News:Tuberculosis Is Still A Major Health Threat In Africa 2
300XL System, English (U.K. cord), 100-240 VAC....
Micro-mini fiber optic light....
Micro-mini fiber optic light....
The MC-3 allows for simultaneous use of two lamps, with an additional built-in spare....
Medicine Products: